UFP Technologies, Inc.

UFP Technologies, Inc. (UFPT) Market Cap

UFP Technologies, Inc. has a market capitalization of .

No quote data available.

CEO: Mitchell C. Rock

Sector: Healthcare

Industry: Medical - Devices

IPO Date: 1993-12-17

Website: https://www.ufpt.com

UFP Technologies, Inc. (UFPT) - Company Information

Market Cap: -|Sector: Healthcare

Company Profile

UFP Technologies, Inc. specializes in the engineering and custom fabrication of components, subassemblies, finished products, and packaging, primarily utilizing advanced foams, films, and plastics. A significant portion of its business is dedicated to the medical sector, where its single-use and single-patient devices and parts are integral to a broad spectrum of applications, including general medical devices, disposable wound care, infection control, minimally invasive surgical tools, wearable technologies, orthopedic soft goods, and protective packaging for orthopedic implants. Beyond healthcare, the company extends its expertise to the automotive, aerospace and defense, consumer, electronics, and industrial markets. Here, its engineered products and components are incorporated into diverse items such as military uniform and gear, automotive interior trim, athletic padding, sustainable protective packaging, air filtration systems, abrasive nail files, and custom protective cases and inserts. UFP Technologies markets and distributes its offerings across the United States, predominantly through a direct sales force supported by independent manufacturer representatives. The company, established in 1963, is headquartered in Newburyport, Massachusetts.

Analyst Sentiment

71%
Buy

From 4 Active Polls

1Y Forecast: $298.00

▲ +0.0% Potential Upside

Consensus Target Metrics

Low Bound

$252

Median

$298

High Bound

$344

Average

$298

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$298.00
▲ +16.96% Upside
Low Target
$252.00
-1% Risk
Median Target
$298.00
17% Mid
High Target
$344.00
35% Max

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

Sentiment volume allocation data unavailable.

Historical valuation matrix unavailable.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 UFP TECHNOLOGIES INC (UFPT) — Investment Overview

🧩 Business Model Overview

UFP Technologies is a manufacturer of engineered components and systems for industrial end markets, with a focus on products that require design integration, tight tolerances, and customer qualification. The value chain centers on converting material inputs (such as metals and engineered polymers) into finished parts and sub-assemblies through machining, forming, molding, and assembly processes, followed by delivery under customer program schedules.

A key feature of the model is that many product lines are tied to OEM platform lifecycles and program requirements. This creates operational and engineering “stickiness” through established specifications, validated quality systems, and production tooling/knowledge embedded in the manufacturing footprint.

💰 Revenue Streams & Monetisation Model

Revenue is primarily generated from manufacturing volumes tied to customer production programs. Monetisation is typically unit-driven, with some degree of revenue continuity coming from repeat purchase on qualified programs and ongoing demand for replacement or follow-on variants.

Margin performance is driven by:

  • Product and process mix (higher complexity parts and value-added assemblies generally carry better contribution margins).
  • Manufacturing utilization (fixed-cost absorption is important in industrial component businesses).
  • Program ramp execution (early cost control during launch phases affects longer-run unit economics).
  • Input cost pass-through and sourcing leverage (where contracts and hedging practices allow partial mitigation of material volatility).

🧠 Competitive Advantages & Market Positioning

UFPT’s competitive position is best characterized as a combination of switching costs (via customer qualification and tooling), manufacturing know-how, and cost efficiency from specialization in engineered production. The moat is less about brand and more about being a qualified, reliable production partner that can meet specification requirements at scale.

  • Switching Costs (Customer Qualification + Tooling): Once a supplier is qualified and tooling/process parameters are validated for a specific program, moving production typically requires re-qualification and customer approval. This raises the effective cost and time risk of switching.
  • Operational Quality Intangibles: In precision components, defects are costly. Documented quality systems, stable yields, and consistent delivery performance become embedded advantages that competitors must replicate.
  • Cost Advantages from Process Expertise: Specialization and economies of scale in specific manufacturing processes can lower unit costs when production volumes are supportive.

Competitive benchmarking: The company competes for engineered component content against established Tier-1 and specialty manufacturers such as Magna International, Lear Corporation, and Adient (in segments where vehicle interior/adjacent engineered content is relevant), as well as other precision industrial component suppliers. Compared with these larger diversified peers, UFPT’s positioning is more focused on manufacturing execution and program-specific engineering content, which can concentrate expertise and reduce customer requalification risk.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, UFPT’s growth outlook is supported by structural demand for engineered content and ongoing platform evolution:

  • Platform lifecycle replacement and follow-on programs: Qualified parts often extend across revisions and new variants, supporting demand continuity when customer programs persist.
  • Lightweighting and design for performance: Adoption of engineered materials and process-intensive manufacturing can increase the value of specialized components.
  • Manufacturing localization and supply-chain resilience: Customers increasingly value suppliers with proven execution, capacity flexibility, and predictable quality.
  • Content expansion per vehicle/product: Engineering-driven complexity can raise the bill-of-material content embedded in each unit, improving addressable revenues even without pure volume growth.

In TAM terms, UFPT’s opportunity is less about broad population growth and more about share of wallet within industrial and transportation-linked build programs—where qualification barriers and process capability can translate into sustained ordering.

⚠ Risk Factors to Monitor

  • End-market cyclicality: Manufacturing components are exposed to production swings and demand timing from OEM customers.
  • Customer program concentration and launch execution: New program ramps can pressure margins; loss of a program or delayed ramp can affect utilization and cash flow.
  • Input cost volatility: Material and logistics cost movements can compress margins unless mitigated through contracts, sourcing, or pricing actions.
  • Capital intensity and footprint risk: Expansions or new tooling require disciplined returns; underutilization can impair earnings power.
  • Technological and design displacement: Lightweighting and alternative architectures (including electrification-driven redesigns) can shift component requirements away from incumbent designs.

📊 Valuation & Market View

The market typically values companies like UFPT using a combination of EV/EBITDA, earnings power/FCF durability, and enterprise-level risk adjustments, reflecting industrial earnings cyclicality. Valuation sensitivity is often driven by:

  • Evidence of margin stability through cycle (or credible normalization assumptions).
  • Utilization outlook and visibility on customer program awards.
  • Working-capital discipline (inventory, receivables, and payables management).
  • Quality and delivery performance, which affects chargebacks, rework, and customer confidence.

Because the business is ultimately tied to manufactured output, investors typically underwrite a trajectory of normalized operating margins and resilient free cash generation rather than relying on perpetual growth narratives.

🔍 Investment Takeaway

UFPT’s long-term investment case rests on manufacturing-centered switching costs—qualification, process validation, and embedded quality execution—combined with the ability to capture engineered content tied to customer platform lifecycles. The core question for sustained returns is not demand growth alone, but UFPT’s capacity to maintain program wins, protect unit economics through utilization cycles, and continue adding value through process expertise as product designs evolve.


⚠ AI-generated — informational only. Validate using filings before investing.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"UFPT reported Q1’26 revenue of $154.2M and net income of $17.5M (EPS $2.27). QoQ (vs 2025-12-31), revenue rose ~3.5% (from $148.9M) while net income was essentially flat at -0.4% (from $17.6M). YoY (vs 2025-03-31), revenue increased ~4.1% and net income increased ~1.9%. Profitability held up: gross margin expanded slightly (28.17% vs 28.18% QoQ broadly flat; and vs 28.45% YoY slightly lower), while operating margin improved vs Q4 (15.15% vs 14.44% QoQ). Net margin was marginally lower vs Q4 (11.35% vs 11.80%) but similar vs last year (11.35% vs 11.60%). Cash flow quality is mixed: operating cash flow was only $3.2M in Q1’26 versus $16.8M QoQ, resulting in modest free cash flow of $1.5M, down sharply due to working-capital/non-cash timing effects. Balance sheet resilience remains solid with equity of $438.9M and total assets of $674.7M; net debt increased to ~$117.6M (from ~$134.2M at Q4). Shareholder returns are likely driven more by fundamentals than momentum: the provided price data shows ~-1.5% 1Y change and no dividend/buyback activity, so total shareholder return momentum is limited. With no cash returns and working-capital noise in cash generation, the setup looks more “steady earnings” than “strong cash/returns.”"

Revenue Growth

Positive

Q1’26 revenue grew ~3.5% QoQ (to $154.2M) and ~4.1% YoY (vs $148.1M in Q1’25), indicating stable top-line momentum.

Profitability

Neutral

Operating margin improved QoQ (15.15% vs 14.44%), but net margin declined vs Q4 (11.35% vs 11.80%). YoY net margin was slightly lower (11.35% vs 11.60%).

Cash Flow Quality

Caution

FCF dropped to ~$1.5M in Q1’26 from ~$13.0M QoQ, while OCF fell to $3.2M (from $16.8M). Net income remains profitable, but cash conversion was weak in the latest quarter.

Leverage & Balance Sheet

Positive

Equity increased to ~$438.9M and total assets rose to ~$674.7M. Net debt improved to ~$117.6M (from ~$134.2M QoQ), suggesting improving leverage/resilience.

Shareholder Returns

Fair

No dividends and no buybacks were reported in the quarter. Price momentum is limited with ~-1.5% 1Y change, so total return support appears weak.

Analyst Sentiment & Valuation

Positive

Consensus price target is ~$298 vs current price $202.38 (material upside implied). Valuation metrics indicate the stock is still priced for growth, but targets are constructive.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

UFPT delivered Q1 2026 revenue growth of 4.1% (medical +5.9%, nonmedical -15%), with expansion led by robotic surgery (+7%), patient surfaces & support (+11%), and interventional & surgical (+15%). The key offset was Wound Care, where two major customers slowed due to excess inventory, with management guiding to roughly a ~3-quarter drag before normalization. Gross margin rose 30 bps to 28.8%, helped by a >200% Santiago revenue increase that leveraged fixed overhead, though AJR labor inefficiencies and simultaneous start-up costs pressured EPS. Adjusted EPS was $2.48 (up slightly), while adjusted operating margin was 16.7% of sales. Management attributed Q2 revenue timing to ~$1 million pushed from a cyber event and flagged tariff net-down benefits partially offset by oil-driven raw material inflation. Operationally, 4 program launches (3 brand-new) and capacity additions in Santiago/La Romana support acceleration in 2H, with profitability improving as start-up costs are absorbed by ramping revenue.

AI IconGrowth Catalysts

  • Robotic surgery segment growth of 7% (start-to-year above original forecast; new programs still early ramp).
  • Patient surfaces & support growth of 11%, supported by capacity build-out and program ramp timing.
  • Interventional and surgical segment growth of 15%.
  • More than 200% revenue increase in Santiago, Dominican Republic from cost leverage/fixed overhead absorption.
  • Robotic surgery and infection prevention program execution tied to 4 simultaneous customer launches, expected to contribute meaningfully in 2H.

Business Development

  • Named customer: Intuitive (management expects less dominance from one large robotics customer; growth becoming more diversified within Intuitive).
  • AJR: labor inefficiency issues tied to E-Verify/legal right to work process and backlog management (referenced as a key profitability driver).
  • 3 of the 4 ramping program customers have already asked UFPT to double capacity on the new programs (no customer names disclosed beyond Intuitive/AJR references).
  • Two facilities/partnership execution: co-investing with customers on new buildings in Santiago, DR and La Romana, DR.

AI IconFinancial Highlights

  • Revenue +4.1% YoY; medical sales +5.9%; nonmedical sales -15%.
  • Robotic surgery +7%, patient surfaces & support +11%, interventional and surgical +15%; Wound Care declined as 2 major customers slowed due to excess inventory.
  • Gross margin increased to 28.8% from 28.5% last year (+30 bps).
  • Adjusted operating margin: 16.7% of sales (no explicit expectation/basis stated).
  • Adjusted EPS diluted: $2.48, up slightly vs last year; EPS grew more slowly than revenue due to start-up costs from 4 program launches, AJR softness, and nonrecurring legal expenses.
  • Incremental sales: ~$1 million pushed into Q2 due to a cyber event at a key customer.
  • Cash from operations: ~$3.2 million (lower than typical) due to stronger March driving working capital needs.
  • Capital expenditures: $1.7 million in the quarter.
  • Debt paydown: paid down ~ $4 million since March 31; leverage ratio ~1.14x.

AI IconCapital Funding

  • Debt: reduced by approximately $4 million since March 31.
  • Leverage ratio: approximately 1.14x at quarter end.
  • Cash from operations: ~$3.2 million in Q1 2026; lower than typical due to working capital needs.
  • Capital expenditures: $1.7 million.

AI IconStrategy & Ops

  • 4 simultaneous program launches; 3 brand-new and 1 transfer; revenue ramps expected to accelerate in 2H with robust contributions in Q3/Q4.
  • Start-up cost headwinds for profitability tied to hiring/training before volume; management expects smooth improvement as revenue ramps (fixed costs largely absorbed by higher revenue).
  • AJR: labor inefficiency headwinds from turnover following E-Verify/legal right to work process last year; backlog reduction underway with overtime inefficiency diminishing.
  • Facility expansion: new buildings in Santiago, DR and La Romana, DR; co-investing with customers; expected possession in Q2.
  • La Romana campus: 6th building added; ~1/6 more capacity, dominantly robotic surgery (infection prevention in another building).
  • Santiago: adding 3rd building, predominantly patient surfaces and support; potential future low-cost country applications directed short-term to La Romana (more mature quality systems/experience).

AI IconMarket Outlook

  • Organic sales growth essentially flat in Q1 due to slow ramping new programs and continued non-medical softness; new program revenue growth anticipated to accelerate in 2H.
  • Robotic surgery growth: new programs expected to become progressively larger contributors over time.
  • Wound Care: management expects ~3-quarter impact from wound care inventory slowdown, then normalization; overlaying new programs next year.
  • AJR profitability: management expects a smooth plus as Santiago comes up and transfers reduce pressure and overtime inefficiency.
  • M&A framing: management expects acquisition growth to represent ~50% of overall growth over multiple years (timing uncertain).

AI IconRisks & Headwinds

  • Wound Care drag: 2 major wound care customers slowed temporarily due to excess inventory; management cites 8-month range of impact to them, but expects ~3-quarter impact to UFPT.
  • Start-up costs: profitability pressured by simultaneous ramp of 4 programs (slow starts; meaningful contribution expected 2H).
  • AJR labor inefficiency and backlog: turnover issues related to E-Verify/legal right to work process; overtime with less efficient crew until backlog reduces.
  • Cyber incident: nonrecurring legal expenses ~$0.5 million due to cyber breach; also ~$1 million sales pushed into Q2.

Q&A: Analyst Interest

  • Topic: Robotics segment growth drivers and Intuitive customer concentration. Management said 7% robotics growth is primarily from existing/anchor programs; new launched programs are still in infancy but expected to become larger contributors over time. They emphasized diversification within Intuitive and reduced future dominance from one customer.
  • Topic: Profitability impact timeline for the 4 ramping programs and duration of start-up costs. Management explained start-up costs are tied to staffing, training, and readiness before volume arrives; as volume ramps, fixed costs are absorbed by higher revenue. They expect robust contributions from the three brand-new programs by the second half of the year with a smooth plus.
  • Topic: Wound Care inventory slowdown magnitude and normalization confidence. Management described two large wound care customers with excess inventory; each believed impact was in an ~8-month range. UFPT expects roughly a three-quarter drag from the slowdown and then normalization, while remaining bullish long term and expecting new programs next year to overlay.

Sentiment: MIXED

Note: This summary was synthesized by AI from the UFPT Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
© 2026 Stock Market Info — UFP Technologies, Inc. (UFPT) Financial Profile